ERBB2 and cancer: The epidermal growth factor receptor (EGFR) family ErbB1 and ErbB2, stem cell factor (SCF)-KIT, and vascular endothelial growth factor receptor 3 (VEGFR3) pathways, major pathways related to cancer aggressiveness (Fig. 5B), were downregulated.